Agata Raniszewska1,2, Małgorzata Polubiec-Kownacka3, Elzbieta Rutkowska2, Joanna Domagala-Kulawik4. 1. Department of Pathology, Medical University of Warsaw, Pawinskiego 7 Street, 02-106, Warsaw, Poland. 2. Department of Internal Medicine and Hematology Laboratory of Flow Cytometry, u, Szaserow 128 Street, 04-141, Warsaw, Poland. 3. Department of Surgery, Institute of Tuberculosis and Lung Diseases, Plocka 26 Street, 01-138, Warsaw, Poland. 4. Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Banacha 1a Street, 02-097, Warsaw, Poland. jdomagala@wum.edu.pl.
Abstract
OBJECTIVES: An immunotherapy was found to be effective in achieving long-term survival in some lung cancer patients. It has emerged to searching for new immune biomarkers for select the best candidates to this therapy. It is suggested that cancer stem cells (CSCs) are responsible for tumor initiation, maintenance and its metastatic potential. However, a role of CSCs in escape of cancer from immunosurveillance is unknown. The aim of the study was assess the phenotype of putative CSCs and to examine the expression of PD-L1 on CSCs in metastatic lymph nodes (LNs) in lung cancer patients. MATERIAL AND METHODS: Flow cytometry was used for CSCs evaluation in peripheral blood and EBUS/TBNA aspirates from N1,N2 lymph nodes in lung cancer patients. RESULTS: Of 30 patients the LNs metastases were confirmed in 18 patients. We noticed presence of PD-L1 on putative lung CSCs- CD133 + EpCAM+ cells. A higher percentage of CD133 + EpCAM+PD-L1+ cells was observed in patients with metastatic in LNs- median value = 4.38% than in patients without LNs metastases- median value = 0,015% (p < 0.05). The highest proportion of PD-L1+ CSCs was found in adenocarcinoma patients and in those with oncogene addiction what indicate an particular biology of this type of lung cancer. CONCLUSION: The presence of CSCs with expression of PD-L1 in the metastatic LNs might suggest their immunogenic potential. EBUS/TBNA is commonly used in diagnosis and staging of lung cancer, so the analysis of the cells in metastatic LNs may fit in "immunoscoring" before immunotherapy.
OBJECTIVES: An immunotherapy was found to be effective in achieving long-term survival in some lung cancerpatients. It has emerged to searching for new immune biomarkers for select the best candidates to this therapy. It is suggested that cancer stem cells (CSCs) are responsible for tumor initiation, maintenance and its metastatic potential. However, a role of CSCs in escape of cancer from immunosurveillance is unknown. The aim of the study was assess the phenotype of putative CSCs and to examine the expression of PD-L1 on CSCs in metastatic lymph nodes (LNs) in lung cancerpatients. MATERIAL AND METHODS: Flow cytometry was used for CSCs evaluation in peripheral blood and EBUS/TBNA aspirates from N1,N2 lymph nodes in lung cancerpatients. RESULTS: Of 30 patients the LNs metastases were confirmed in 18 patients. We noticed presence of PD-L1 on putative lung CSCs- CD133 + EpCAM+ cells. A higher percentage of CD133 + EpCAM+PD-L1+ cells was observed in patients with metastatic in LNs- median value = 4.38% than in patients without LNs metastases- median value = 0,015% (p < 0.05). The highest proportion of PD-L1+ CSCs was found in adenocarcinomapatients and in those with oncogene addiction what indicate an particular biology of this type of lung cancer. CONCLUSION: The presence of CSCs with expression of PD-L1 in the metastatic LNs might suggest their immunogenic potential. EBUS/TBNA is commonly used in diagnosis and staging of lung cancer, so the analysis of the cells in metastatic LNs may fit in "immunoscoring" before immunotherapy.
Entities:
Keywords:
Cancer stem cells; EBUS/TBNA; EpCAM; Lung cancer; PD-L1
Authors: Matthew G Krebs; Robert Sloane; Lynsey Priest; Lee Lancashire; Jian-Mei Hou; Alastair Greystoke; Tim H Ward; Roberta Ferraldeschi; Andrew Hughes; Glen Clack; Malcolm Ranson; Caroline Dive; Fiona H Blackhall Journal: J Clin Oncol Date: 2011-03-21 Impact factor: 44.544
Authors: Ryan Morrison; Stephen M Schleicher; Yunguang Sun; Kenneth J Niermann; Sungjune Kim; Daniel E Spratt; Christine H Chung; Bo Lu Journal: J Oncol Date: 2010-10-12 Impact factor: 4.375
Authors: Tobias Schatton; Ute Schütte; Natasha Y Frank; Qian Zhan; André Hoerning; Susanne C Robles; Jun Zhou; F Stephen Hodi; Giulio C Spagnoli; George F Murphy; Markus H Frank Journal: Cancer Res Date: 2010-01-12 Impact factor: 12.701
Authors: Shyamala Maheswaran; Lecia V Sequist; Sunitha Nagrath; Lindsey Ulkus; Brian Brannigan; Chey V Collura; Elizabeth Inserra; Sven Diederichs; A John Iafrate; Daphne W Bell; Subba Digumarthy; Alona Muzikansky; Daniel Irimia; Jeffrey Settleman; Ronald G Tompkins; Thomas J Lynch; Mehmet Toner; Daniel A Haber Journal: N Engl J Med Date: 2008-07-02 Impact factor: 91.245
Authors: Rebecca M O' Brien; Jason McGrath; Noel E Donlon; Maria Davern; Ashanty M Melo; Croí E Buckley; Andrew D Sheppard; John V Reynolds; Niamh Lynam-Lennon; Stephen G Maher; Joanne Lysaght Journal: Sci Rep Date: 2022-02-28 Impact factor: 4.379